ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … mars 17, 2021
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … juillet 21, 2020
ProQR Appoints Theresa Heggie as Chief Commercial Officer Press release … with a focus on inherited retinal diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … octobre 04, 2021
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … février 16, 2021
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … mars 07, 2022
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … décembre 30, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Press release … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … mai 04, 2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. décembre 16, 2021
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Press release … with a focus on inherited retinal diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis … septembre 08, 2021
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Press release … investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G … août 01, 2023